Baker Bros. Advisors Boosts Stake in Madrigal Pharmaceuticals

Hedge fund increases position in biopharmaceutical company by 8.4% in Q3

Mar. 15, 2026 at 8:35am

Got story updates? Submit your updates here. ›

Baker Bros. Advisors LP, a major hedge fund, increased its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 8.4% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission. The firm now owns approximately 2.14 million shares, or 9.43% of the biopharmaceutical company's outstanding stock, valued at over $982 million.

Why it matters

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular, metabolic, and liver diseases, with a lead candidate in Phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH). The increased stake by a prominent healthcare-focused hedge fund like Baker Bros. Advisors signals confidence in the company's pipeline and future prospects.

The details

According to the 13F filing, Baker Bros. Advisors purchased an additional 165,683 shares of Madrigal Pharmaceuticals during the third quarter, bringing its total position to 2,141,701 shares. This represents approximately 9.43% of the company's outstanding stock. Madrigal Pharmaceuticals is the third-largest holding in Baker Bros. Advisors' portfolio, underscoring the firm's conviction in the company's potential.

  • Baker Bros. Advisors increased its stake in Madrigal Pharmaceuticals during the third quarter of 2026.

The players

Baker Bros. Advisors LP

A prominent hedge fund that focuses on investments in the healthcare and biotechnology sectors.

Madrigal Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing innovative therapies for cardiovascular, metabolic, and liver diseases, including a lead candidate in Phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH).

Got photos? Submit your photos here. ›

The takeaway

The increased stake by Baker Bros. Advisors in Madrigal Pharmaceuticals underscores the hedge fund's confidence in the company's pipeline and future growth potential, particularly in the development of its lead NASH candidate. This investment signals that the biopharmaceutical firm remains an attractive target for healthcare-focused investors.